Should we vaccinate the better seroconverters or the most vulnerable? Game changing insights for COVID-19 vaccine prioritization policies

Abstract

Background With the rapid rise in COVID 19 cases incomparable to the number of vaccinations available, there has been a demand to prioritize the older age groups receiving the vaccine as they have more risk of morbidity and mortality and thus better outcome from vaccination. Main body Some studies showed a lower seroconversion rate in older group patients; thus, we discuss the necessity to reprioritize vaccinations to younger age groups who have better seroconversion rates, but we may face some ethical dilemma that could hinder our hypothesis. Decreased seroconversion rates in adults are attributable to immuno-senescence which involves a decrease in humoral and cellular-mediated immunity with age. Despite this fact, there remains some ethical dilemma that can hinder widespread vaccination of younger generations, the most important of which is the unknown long-term effects of COVID-19 vaccines due their fast-tracking under the pressure of the pandemic. Short conclusion Prioritizing children vaccination against COVID-19 seems an interesting strategy that can help in containing the pandemic. Resolving some ethical dilemma needs to be done before implementing such strategy.

The role of peroxisome proliferator-activated receptors in the modulation of hyperinflammation induced by SARS-CoV-2 infection: A perspective for COVID-19 therapy

“…Intriguingly, PPARa and PPARg have been proposed as effective adjuvants for the development of COVID-19 vaccines because these receptors through an increase in the population of regulatory T-cells via upregulation in FOXP3 mRNA expression (a transcriptional factor for the function and differentiation of regulatory T-cells) (1): stimulate memory T-cells (2), upregulate the gd type of T-cells, and (3) prolong B-cell memory and improve the secondary antibody response and thus can induce long-term memory (176,178). However, the inverse relationship between regulatory T-cells and chronic inflammation has been revealed by previous research (175,179), and the anti-inflammatory properties of these cells are well established (180,181).…”